Vitiligo: when the pigment cells are gone, not just switched off

A switch is no use without a bulb — so first the skin must be given back its pigment cells, and only then told to shine.

Vitiligo is the melanocortin pigment story told in the negative. Most of this site is about tuning the pigment signal — turning MC1R up or down to make more or less melanin. Vitiligo is what happens when there is nothing left to tune: the immune system has destroyed the melanocytes themselves, the pigment cells, leaving smooth white patches where no pigment can be made at all.^[2] That single fact shapes everything about how — and whether — the melanocortin system can help.

A missing bulb, not a flipped switch

It is worth being precise about the difference, because it explains why vitiligo is hard. In a tanning context, MC1R is a dimmer switch on a working light: push the receptor and the melanocyte makes more dark eumelanin. In vitiligo the light itself has been removed. Vitiligo is an autoimmune condition — the body’s own T cells target and kill melanocytes, and the patches that result are not under-stimulated, they are unpopulated.^[2]Hand such a patch a pigment-driving signal and there is nothing there to receive it. An MC1R agonist, on its own, has no cells to act on.

The two-step the melanocortin angle depends on

This is why the melanocortin approach to vitiligo is not a drug but a pairing. Repigmenting a patch takes two distinct things, in order. First the skin has to be given back its pigment cells: melanocyte precursors, which survive in a reservoir in the hair follicles, must be mobilized and coaxed to migrate out into the bare skin. Standardnarrowband-UVB phototherapy — the mainstay of vitiligo treatment — is what does this. Only once the cells are present does the second step make sense: driving them to proliferate and actually manufacture pigment, which is exactly what an afamelanotide-style MC1R agonist does.^[1][3]

What the trial actually showed

The idea has been tested. A randomized, multicenter trial compared afamelanotide plus narrowband UVB against narrowband UVB alone, and the combination produced faster and more complete repigmentation in a subset of patients — the benefit was clearest in people with darker skin types, whose melanocytes respond strongly to the MC1R signal.^[1] It was not a uniform cure: response varied, the drug added the melanocortin class’s own effects (notably generalized skin darkening, which in vitiligo can increase the contrast with the patches during treatment), and the evidence base remains far smaller than for afamelanotide’s approved use. But it was a genuine demonstration that the pigment switch, correctly timed, can help refill what autoimmunity has emptied.

The honest bottom line

Vitiligo is a useful corrective to the rest of this site’s pigment pages: the melanocortin system can command pigment, but only where there are living melanocytes to obey. That is why the approach here is combination therapy and why it is still investigational rather than approved — afamelanotide’s license is for erythropoietic protoporphyria, not vitiligo.^[3] For the receptor at the centre of it, see MC1R; for the approved drug being repurposed, see afamelanotide; and for why skin darkening rides along with any MC1R agonist, see the trade-off.